Zenas BioPharma grants 150,000 stock options

Zenas BioPharma, Inc. reported that officer Lisa von Moltke received a grant of stock options covering 150,000 shares of common stock.

Rhea-AI Filing Summary

Zenas BioPharma, Inc. reported that officer Lisa von Moltke received a grant of stock options covering 150,000 shares of common stock. The options have an exercise price of $18.71 per share and expire on June 15, 2036.

The grant vests as to 25% of the underlying shares on June 15, 2027, the first anniversary of the vesting commencement date. The remaining 75% vests in equal monthly installments over the following 36 months, subject to her continued service. Following this award, she holds 150,000 stock options directly.

Insider Trade Summary

Grant/Award: 150,000 shares

Grant/Award 1 txn

Insider von Moltke Lisa

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	150,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 150,000 contracts (Direct)

Footnotes (1)

1. F1. The option vests as to 25% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.

Key Figures

Option grant size: 150,000 options Exercise price: $18.71 per share Expiration date: June 15, 2036 +3 more

6 metrics

Option grant size 150,000 options Stock Option (Right to Buy) granted to officer

Exercise price $18.71 per share Conversion or exercise price of options

Expiration date June 15, 2036 Option term end date

Underlying shares 150,000 shares Common stock underlying the options

Post-transaction options held 150,000 options Total options directly owned after grant

Initial vesting date June 15, 2027 25% of underlying shares vest

Key Terms

Stock Option (Right to Buy), exercise price, underlying shares of common stock, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price of $18.7100 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

underlying shares of common stock financial

"The option vests as to 25% of the underlying shares of common stock"

vesting financial

"vests as to 25% on June 15, 2027 and monthly over 36 months thereafter"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Zenas BioPharma (ZBIO) report for Lisa von Moltke?

Zenas BioPharma reported a stock option grant to officer Lisa von Moltke for 150,000 shares of common stock. This is a compensation-related award, not an open-market stock purchase or sale, and reflects equity-based pay aligned with the company’s long-term performance.

What are the key terms of Lisa von Moltke’s stock options at Zenas BioPharma (ZBIO)?

The options cover 150,000 shares of common stock at an exercise price of $18.71 per share and expire on June 15, 2036. They give her the right to buy shares at that fixed price if vesting and service conditions are met.

How do Lisa von Moltke’s Zenas BioPharma (ZBIO) options vest over time?

Twenty-five percent of the options vest on June 15, 2027. The remaining 75% then vest in equal monthly installments over 36 months, so full vesting occurs over four years total, provided she continues to serve the company throughout that period.

Does the Form 4 show Lisa von Moltke buying or selling Zenas BioPharma (ZBIO) shares?

The Form 4 shows an acquisition of derivative securities via a stock option grant, not a market trade. It records a grant/award of options to purchase 150,000 shares, with no open-market buying or selling of common stock in this transaction.

How many Zenas BioPharma (ZBIO) stock options does Lisa von Moltke hold after this grant?

After the reported transaction, Lisa von Moltke directly holds 150,000 stock options. These options are tied to the company’s common stock and are subject to the disclosed exercise price, expiration date, and multi-year vesting schedule based on her continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 06:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

von Moltke Lisa

(Last) (First) (Middle)

C/O ZENAS BIOPHARMA, INC.

852 WINTER ST., SUITE 250

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Zenas BioPharma, Inc. [ ZBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$18.71	06/15/2026		A		150,000		(1)	06/15/2036	Common Stock	150,000	$0	150,000	D

Explanation of Responses:

1. The option vests as to 25% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.

Remarks:

Head of Research and Development and Chief Medical Officer

	By: /s/ Jeffrey Held, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)